|REACH 3 study: A phase III randomized open-label multi-center study of ruxolitinib vs. best available therapy in patients with corticosteroid-refractory chronic graft vs host disease after allogenic stem cell transplantation.
|Dr. Husam Abu Jazar
|Safety and Efficacy of Dasatinib 50 mg in First Line Treatment of Early Chronic Phase Chronic Myeloid Leukemia.
|Dr. Kamal Al-Rabi
|A phase II, open-label, single arm study to evaluate the safety, efficacy, and pharmacokinetics of twice daily midostaurin (PKC412) combined with standard chemotherapy and as a single agent post-consolidation therapy in children with untreated FLT3-mutated AML.
|Dr. Mayada Abu Shanab